摘要
目的验证吸烟能否使冠心病患者冠状动脉介入治疗(PCI)术后近期氯吡格雷抗血小板活化的作用增强。方法入选择期行冠脉造影并成功行冠脉介入治疗(PCI)的不稳定心绞痛患者42例,分为吸烟组(22例)和非戒烟组(20例)。各组入院后均给予氯吡格雷300mg顿服,术后继续每日给予氯吡格雷75mg口服。服药前以流式细胞仪测定各组CD61、CD62p的阳性表达率;术后24、72h再次测定CD61、CD62p的阳性表达率。结果 PCI术后24h两组的CD61、CD62p表达较术前无显著变化(CD61:-1.16%±19.06%vs-0.98%±22.19%,P=0.36;CD62p:-1.93%±10.80%vs-2.07%±15.49%,P=0.96);PCI术后72h吸烟组CD61、CD62p表达较术前有下降趋势,而非吸烟组无下降趋势(CD61:-2.19%±21.72%vs 5.27%±26.58%,P=0.46;CD62p:-6.13%±18.74%vs 0.12%±12.78%,P=0.25),但是这些差异无统计学意义。结论吸烟未增强冠心病患者PCI术后近期氯吡格雷的抗血小板活化作用。本实验未能验证吸烟能增强冠心病患者PCI术后近期氯吡格雷的抗血小板活化作用这一结论。
Objective To confirm if cigeratte smoke could enhance the role of clopidogrel against platelet activation in early post - PCI patients. Methods Totally 42 patients with unstable coronary artery disease undergoing elective coronary angiography and successful intervention （PCI） , were selected, and divided into smoking group （22 cases） and non- smoking cessation group （20 cases）. Each group as given 300mg elopidogrel at once after admission and followed with 75mg daily. CD61, CD62p positive rate of expression were de- terminated by flow cytometry before the medication and re - determinated after 24, 72h of PCI. Results The changes of CD61, CD62p expression in both groups after 24h PCI had no significant difference（CD61 ： - 1. 16% ±19.06% vs - 0.98% ± 22. 19% ,P = 0.36; CD62p： - 1.93% ＋ 10.80% vs - 2.07% ± 15.49% ,P =0.96）. In smoking group 72h after PCI, CD61, CD62p expression was still lower than before, while the non - smoking group had no longer the performance（ CD61 ： - 2.19% ± 21.72% vs 5.27% ± 26.58% ,P = 0.46;CD62p： -6. 13% ± 18.74% vs 0.12%± 12.78% ,P = 0.25 ） , but these differences were not statistically significant. Conclusion Smoking doesn＇t significantly increase the antiplatelet of clopidogrel in early post - PCI. This study failed to verify the conclusion that smoking could increase the antiplatelet of clopidogrel in early post - PCI.
出处
《医学研究杂志》
2012年第3期127-130,共4页
Journal of Medical Research
关键词
吸烟
冠心病
活化血小板
氯吡格雷
Smoking
Coronary heartdisease
Activated platelet
Clopidogrel
